Previous Article | Next Article ![]()
Infection and Immunity, June 2006, p. 3488-3497, Vol. 74, No. 6
0019-9567/06/$08.00+0 doi:10.1128/IAI.02006-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Departments of Medical Biochemistry,1 Medical Microbiology and Immunology, Institute of Biomedicine, Göteborg University, S-405 30 Göteborg, Sweden2
Received 13 December 2005/ Returned for modification 16 February 2006/ Accepted 30 March 2006
|
|
|---|
|
|
|---|
Expression of four genes (cfaABCE) in the CFA/I operon is required for assembly of CFA/I fimbriae (17). The same is true for CS1 (cooBACD) and CS2 (cotBACD) (30). cfaB encodes the major pilin subunit (corresponding to cooA and cotA in CS1 and CS2, respectively), whereas cfaE (cooD and cotD) encodes a minor tip protein. The cfaA (cooB and cotB) gene product is a chaperone-like protein, and cfaC (cooC and cotC) encodes a protein involved in transport of fimbriae across the outer membrane.
The adhesion of fimbriated bacteria to host epithelium may be mediated by the major fimbrial subunit as in K99 fimbriae (16) or the minor tip protein as in P fimbriae (21). In the case of CFA/I, it has been proposed that adhesion is via the major subunit (7). However, a point mutation in the tip protein CfaE abolished fimbrially induced hemagglutination (31). A similar result was obtained with CS1 when the corresponding tip protein, CooD, was mutated in the same manner. Furthermore, Fab fragments directed against the N-terminal region of the minor tip protein inhibited both hemagglutination induced by bacteria expressing CFA/I and their ability to bind to Caco-2 cells (1). These results suggest that the minor tip proteins of these fimbriae are involved in adhesion.
Although the genetics and architecture of CFA/I and related fimbriae have been extensively studied, far less is known about their target cell receptors. In the present study, the ability of CFA/I fimbriae, with and without the minor tip protein, to bind to glycosphingolipids from various sources was investigated. Specific interactions could be demonstrated between CFA/I-fimbriated bacteria or purified CFA/I fimbriae and a number of nonacid glycosphingolipids. Interestingly, there appeared to be no difference in binding between CFA/I with or without the minor tip protein, demonstrating that these activities reside with the major CfaB subunit.
|
|
|---|
E. coli recombinant strains were grown in CFA broth containing Casamino Acids (10 g), yeast extract (1.5 g), MgSO4 · 7H2O (102 mg), and MnCl2 · 4H2O (8 mg/liter; pH 7.4) and supplemented with ampicillin (100 µg/ml) at 37°C with shaking. For metabolic labeling, the medium (10 ml) was supplemented with 10 µl of [35S]methionine (400 µCi; Amersham Pharmacia Biotech). After 2 h, 100 µl of isopropyl-ß-D-thiogalactopyranoside (100 mM; Saveen Werner AB, Malmö, Sweden) was added and the bacteria were then incubated overnight. Bacteria were harvested, washed three times in phosphate-buffered saline (PBS, pH 7.3), and then resuspended in PBS containing 2% (wt/vol) bovine serum albumin (BSA), 0.1% (wt/vol) NaN3, and 0.1% (wt/vol) Tween 20 (BSA-PBS-Tween) to a density of 108 CFU/ml. The specific radioactivity of bacterial suspensions was approximately 1 cpm/100 bacteria.
Culture and labeling of H. pylori strain J99 were done as previously described (2).
Immunoelectron microscopy. Aliquots (10 µl) of a bacterial suspension (1010 bacteria/ml in PBS) were applied to Parafilm. Formvar-coated grids were put on the suspensions and left for 2 min with the grids placed 15 cm below a lamp to increase the temperature of the sample. The grids were then washed twice and then incubated for 15 min with 25 µl of monoclonal anti-CFA/I antibody 1:6 (22) diluted to approximately 0.6 µg/ml in PBS-0.1% BSA-0.05% Tween. The grids were washed six times with PBS-1% BSA and then incubated for 15 min with anti-mouse immunoglobulin G-gold conjugate (Amersham) in PBS-0.1% BSA-0.05% Tween. After washing the grids three times with PBS-0.1% BSA and three times with distilled water, negative staining was performed by applying the grids to 25 µl of 1% ammonium molybdate (pH 7.0) for 50 to 60 s, followed by air drying on filter paper for 5 min. The grids were stored at 4°C. The grids were examined with an electron microscope (LEO 912 AB Omega TEM; Carl Zeiss SMT AG, Oberkochen, Germany) operated at 120 kV.
Fimbrial preparations. Different ETEC fimbriae were isolated as described previously (28). In brief, bacteria grown on CFA agar were homogenized with a blender and centrifuged at 12,000 x g for 20 min. The supernatant was precipitated with ammonium sulfate (at 20 and 40% saturation), and after centrifugation at 12,000 x g and dialysis, the pellet was purified by chromatography on a DEAE-Sephadex column. The purity of the different fimbrial preparations was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Coomassie staining (Phastsystem; Pharmacia, Uppsala, Sweden) and by immunoblotting with antisera against whole bacteria expressing the homologous or heterologous fimbriae. The concentration of the fimbriae was determined by inhibition enzyme-linked immunosorbent assay with a highly purified fimbrial preparation as described in reference 22.
125I-labeling. Aliquots of 100 µg of fimbrial preparations were labeled with 125I by using Na-125I (100 µCi/ml; Amersham Pharmacia Biotech, Little Chalfont, United Kingdom), according to the IODO-GEN protocol of the manufacturer (Pierce, Rockford, IL), giving approximately 5 x 103 cpm/µg of protein.
Reference glycosphingolipids. Total acid and nonacid glycosphingolipid fractions were prepared as described earlier (18). Individual glycosphingolipids were isolated by repeated chromatography on silicic acid columns and by high-performance liquid chromatography and identified by mass spectrometry (32), 1H NMR spectroscopy (20), and degradation studies (33, 38).
The glycosphingolipid nomenclature used in this report follows the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (15a). It is assumed that Gal, Glc, GlcNAc, GalNAc, and NeuAc are of the D configuration, Fuc is of the L configuration, and all sugars are present in the pyranose form.
Thin-layer chromatography. Aluminum- or glass-backed silica gel 60 high-performance thin-layer chromatography plates (Merck, Darmstadt, Germany) were used for thin-layer chromatography and eluted with chloroform-methanol-water (60:35:8, by volume) as the solvent system. The different glycosphingolipids were applied to the plates in quantities of 0.1 to 4 µg of pure glycosphingolipids and 40 µg of glycosphingolipid mixtures. Chemical detection was done with anisaldehyde (34).
Chromatogram binding assays. Binding of radiolabeled fimbriae and of bacteria to glycosphingolipids on thin-layer chromatograms was done as described previously (15). Dried chromatograms were dipped in diethyl ether-n-hexane (1:5 vol/vol) containing 0.5% (wt/vol) polyisobutylmethacrylate for 1 min, dried, and then blocked with BSA-PBS-Tween for 2 h at room temperature. Thereafter, the plates were incubated with 125I-labeled fimbriae (1 x 106 to 5 x 106 cpm/ml) or 35S-labeled bacteria (1 x 106 to 5 x 106 cpm/ml) diluted in BSA-PBS-Tween for another 2 h at room temperature. After washing six times with PBS and drying, the thin-layer plates were autoradiographed for 12 h with XAR-5 X-ray films (Eastman Kodak, Rochester, NY).
Chromatogram binding assays with monoclonal antibodies directed against the Lea determinant (Signet Laboratories, Inc., Dedham, MA) were done as previously described (13), by using 125I-labeled anti-mouse antibodies for detection.
Competition experiments.
As a test for possible inhibition of binding by soluble sugars, 10 µg of 125I-labeled CFA/I fimbriae in 100 µl of BSA-PBS-Tween was incubated with lactose (Galß4Glc; J. T. Baker Chemical Co., Phillipsburg, NJ) or Lea pentasaccharide [Galß3(Fuc
4)GlcNAcß3Galß4Glc; IsoSep, Tullinge, Sweden] at a final concentration of 1 mg/ml. Incubations were done for 2 h at room temperature, and then the suspensions were diluted 40 times and used in the chromatogram binding assay as described above.
|
|
|---|
![]() View larger version (45K): [in a new window] |
FIG. 1. Binding of 125I-labeled CFA/I fimbriae to mixtures of glycosphingolipids on thin-layer chromatograms. Chemical detection by anisaldehyde (A) and an autoradiogram obtained by binding of 125I-labeled CFA/I fimbriae (B) are shown. The glycosphingolipids were separated on aluminum-backed silica gel plates with chloroform-methanol-water (60:35:8, by volume) as the solvent system, and the binding assay was performed as described in Materials and Methods. Lanes: 1, nonacid glycosphingolipids of human blood group A erythrocytes (40 µg); 2, nonacid glycosphingolipids of guinea pig intestine (40 µg); 3, nonacid glycosphingolipids of mouse feces (40 µg); 4, nonacid glycosphingolipids of rat intestine (40 µg); 5, nonacid glycosphingolipids of human meconium (40 µg); 6, calf brain gangliosides (40 µg); 7, acid glycosphingolipids of human erythrocytes (40 µg); 8, acid glycosphingolipids of human hypernephroma (40 µg). Autoradiography was performed for 12 h. The roman numerals to the left indicate the approximate numbers of carbohydrate residues in the bands.
|
4Gal motif was indicated by the nonbinding to globotriaosylceramide and globotetraosylceramide, the major compounds of the nonacid glycosphingolipid fractions of human erythrocytes (Fig. 1, lane 1).
Binding of CFA/I fimbriae to pure reference glycosphingolipids.
The concentrations of the various glycosphingolipids in mixtures from natural sources, used in the initial screening for carbohydrate binding, are highly variable. To further define the binding characteristics of the CFA/I fimbriae, a number of pure glycosphingolipids at defined concentrations were next tested in a chromatogram binding assay. The results are summarized in Table 1. The majority of the glycosphingolipids tested, including sulfated compounds (compound 3 in Table 1; Fig. 1, lane 8), gangliosides (compounds 27 to 38; Fig. 1, lanes 6 to 8), and glycosphingolipids with Gal
4Gal core (compounds 21, 23, and 25; Fig. 1, lanes 1 and 2) were not recognized by the fimbriae. Furthermore, lactosylceramide with sphingosine and nonhydroxy fatty acids (compound 4; Fig. 2, lane 2, and presented in Fig. 1, lane 1) was not bound by the CFA/I fimbriae.
|
View this table: [in a new window] |
TABLE 1. Binding of 125I-labeled native CFA/I fimbriae, 35S-labeled recombinant CFA/I-expressing E. coli Top10-CFA/I, and 125I-labeled CFA/I fimbriae with deletion of the CfaE subunit (CFA/I/E) to pure glycosphingolipids on thin-layer chromatograms
|
![]() View larger version (64K): [in a new window] |
FIG. 2. Binding of CFA/I fimbriae, CFA/I/E fimbriae, and recombinant bacterial cells expressing CFA/I fimbriae and CFA/I/E fimbriae to pure glycosphingolipids on thin-layer chromatograms. Shown are chemical detection by anisaldehyde (A) and autoradiograms obtained by binding of CFA/I fimbriae (B), CFA/I/E fimbriae (C), CFA/I-expressing E. coli (strain Top10-CFA/I) (D), and E. coli with CFA/I/E fimbriae (strain Top10-CFA/I/E) (E). The glycosphingolipids were separated on aluminum-backed silica gel plates with chloroform-methanol-water (60:35:8, by volume) as the solvent system, and the binding assays were performed as described in Materials and Methods. Autoradiography was performed for 12 h. Lanes: 1, galactosylceramide (Galß1Cer) (2 µg); 2, glucosylceramide (Glcß1Cer) (2 µg); 3, lactosylceramide (Galß4Glcß1Cer) with d18:1-16:0-24:0 (2 µg); 4, lactosylceramide (Galß4Glcß1Cer) with t18:0-h16:0-h24:0 (2 µg); 5, isoglobotriaosylceramide (Gal 3Galß4Glcß1Cer) (2 µg); 6, neolactotetraosylceramide (Galß4GlcNAcß3Galß4Glcß1Cer) (2 µg); 7, Lea pentaglycosylceramide [Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (2 µg); 8, globotetraosylceramide (GalNAcß3Gal 4Galß4Glcß1Cer) (2 µg).
|
![]() View larger version (30K): [in a new window] |
FIG. 7. Comparison of glycosphingolipid recognition of CFA/I and heterologous CF fimbriae of ETEC. Autoradiograms were obtained by binding of 125I-labeled CFA/I fimbriae (A), CS4 fimbriae (B), and CS7 fimbriae (C) to serial dilutions (0.4 to 2.0 µg) of glycosphingolipids in a chromatogram binding assay. The binding assay was done as described in Materials and Methods. The solvent system used was chloroform-methanol-water (60:35:8, by volume). Autoradiography was performed for 12 h. Lanes: 1 to 4, glucosylceramide (Glcß1Cer), isoglobotriaosylceramide (Gal 3Galß4Glcß1Cer), and gangliotetraosylceramide (Galß3GalNAcß4Galß4Glcß1Cer) (0.4 to 2.0 µg of each compound); 5 to 8, lactosylceramide (Galß4Glcß1Cer) with t18:0-h16:0-h24:0, neolactotetraosylceramide (Galß4GlcNAcß3Galß4Glcß1Cer), and Lea pentaglycosylceramide [Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (0.4 to 2.0 µg of each compound).
|
![]() View larger version (56K): [in a new window] |
FIG. 3. Comparison of glycosphingolipid recognition by CFA/I fimbriae of ETEC and BabA-expressing H. pylori. The glycosphingolipids were chromatographed on aluminum-backed silica gel plates and visualized with anisaldehyde (A). Duplicate chromatograms were incubated with 125I-labeled CFA/I fimbriae (B) and 35S-labeled H. pylori strain J99 (C), followed by autoradiography for 12 h, as described in Materials and Methods. The solvent system used was chloroform-methanol-water (60:35:8, by volume). Lanes: 1, Lea pentaglycosylceramide [Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (2 µg); 2, B type 1 hexaglycosylceramide [Gal 3(Fuc 2)Galß3GlcNAcß3Galß4Glcß1Cer] (2 µg); 3, Lex pentaglycosylceramide [Galß4(Fuc 3)GlcNAcß3Galß4 Glcß1Cer] (2 µg); 4, B hepta-glycosylceramide (Gal 3Galß4GlcNAcß3Galß4GlcNAcß3Galß4Glcß1Cer) (2 µg); 5, Leb hexaglycosylceramide [Fuc 2Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (2 µg); 6, A type 1 heptaglycosylceramide [GalNAc 3(Fuc 2)Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (2 µg); 7, Ley hexaglycosylceramide [Fuc 2Galß4(Fuc 3)GlcNAcß3Galß4Glcß1Cer] (2 µg); 8, A type 2 heptaglycosylceramide [GalNAc 3(Fuc 2)Galß4(Fuc 3)GlcNAcß3Galß4Glcß1Cer] (2 µg); 9, H type 2 pentaglycosylceramide (Fuc 2Galß4GlcNAcß3Galß4Glcß1Cer) (2 µg). Autoradiography was performed for 12 h.
|
3-linked NeuAc was not tolerated (compounds 33, 36, and 37; Fig. 4, lanes 2, 4, and 6). Substitution of the Ley element with GalNAc
3 was also rejected by the fimbriae (compound 15; Fig. 3, lane 7), and substitution of the H-5 type 2 glycosphingolipid with GalNAc
3 or Gal
3 (compounds 13 and 14) also abrogated binding.
![]() View larger version (43K): [in a new window] |
FIG. 4. Binding of CFA-1 fimbriae of ETEC to pure glycosphingolipids on thin-layer chromatograms. Chemical detection by anisaldehyde (A) and an autoradiogram obtained by binding of 125I-labeled CFA-1 fimbriae (B) are shown. The glycosphingolipids were separated on aluminum-backed silica gel plates with chloroform-methanol-water (60:35:8, by volume) as the solvent system, and the binding assays were performed as described in Materials and Methods. Autoradiography was performed for 12 h. Lanes: 1, neolactotetraosylceramide (Galß4GlcNAcß3Galß4Glcß1Cer) (2 µg); 2, sialyl-neolactotetraosylceramide (NeuAc 3Galß4GlcNAcß3Galß4Glcß1Cer) (2 µg); 3, Lex pentaglycosylceramide [Galß4(Fuc 3)GlcNAcß3Galß4Glcß1Cer] (2 µg); 4, sialyl-Lex hexaglycosylceramide [NeuAc 3Galß4(Fuc 3)GlcNAcß3Galß4Glcß1Cer] (2 µg); 5, Lea pentaglycosylceramide [Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (2 µg); 6, sialyl-Lea hexaglycosylceramide [NeuAc 3Galß3(Fuc 4) GlcNAcß3Galß4Glcß1Cer] (2 µg).
|
To estimate the relative affinity of the CFA/I fimbriae for various binding-active glycosphingolipids, the binding of radiolabeled fimbriae to serial dilutions of glycosphingolipids on thin-layer chromatograms was determined (Fig. 5). In this assay, lactosylceramide with phytosphingosine and hydroxy fatty acids (compound 5 in Table 1), isoglobotriaosylceramide (compound 22), neolactotetraosylceramide (compound 8), and the Lea-5 glycosphingolipid (compound 17) were the preferred ligands (detection limit, 0.1 to 0.4 µg), followed by the Lex-5 (compound 10) and Ley-6 (compound 12) glycosphingolipids (detection limit, 0.6 to 0.8 µg), while glucosylceramide (compound 2) gave no signal.
![]() View larger version (37K): [in a new window] |
FIG. 5. Binding of CFA/I fimbriae of ETEC to serial dilutions of glycosphingolipids. Autoradiograms were obtained by binding of 125I-labeled CFA/I fimbriae to serial dilutions (0.1 to 1.0 µg) of glycosphingolipids in a chromatogram binding assay. The binding assay was done as described in Materials and Methods. Autoradiography was performed for 12 h. Lanes in panel A: 1 to 6, glucosylceramide (Glcß1Cer), lactosylceramide (Galß4Glcß1Cer) with t18:0-h16:0-h24:0, isoglobotriaosylceramide (Gal 3Galß4Glcß1Cer), neolactotetraosylceramide (Galß4GlcNAcß3Galß4Glcß1Cer), and Lea pentaglycosylceramide [Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (0.1 to 1.0 µg of each compound); 7, negative control globotetraosylceramide (GalNAcß3Gal 4Galß4Glcß1Cer) (4 µg). Lanes in panel B: 1 to 5, Lea pentaglycosylceramide [Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (0.1 to 0.8 µg); 6 to 10, Lex pentaglycosylceramide [Galß4(Fuc 3)GlcNAcß3Galß4Glcß1Cer] and Ley hexaglycosylceramide [Fuc 2Galß4(Fuc 3)GlcNAcß3Galß4Glcß1Cer] (0.1 to 0.8 µg of each compound).
|
Glycosphingolipid recognition of CFA/I fimbriae without the tip protein (CFA/I/E). To evaluate the relative roles of the major CfaB subunit and the tip subunit CfaE in the glycosphingolipid interaction, a CfaE deletion mutant was constructed. Although the minor tip protein has been proposed to be involved in fimbrial assembly (30), fimbrial structures were produced by the recombinant bacteria as shown in Fig. 6, demonstrating that CfaE is not indispensable for the assembly of CFA/I fimbriae.
![]() View larger version (81K): [in a new window] |
FIG. 6. Electron micrograph of immunolabeled and negatively stained recombinant E. coli expressing CFA/I fimbriae without tip protein CfaE (strain Top10-CFA/I/E). The bacteria were labeled with monoclonal anti-CFA/I antibody 1:6. The bar represents 1 µm.
|
Comparison of glycosphingolipid recognition of CFA/I and heterologous CF fimbriae. To estimate the role of the fimbrial structure in the glycosphingolipid recognition process, the binding of 125I-labeled CS1 and CS4 fimbriae, belonging to the CFA/I group, and CS7 fimbriae, of the CS5 group, was also tested in the chromatogram binding assay. The results are exemplified in Fig. 7, and summarized in Table 2. Thus, the glycosphingolipids recognized by the CFA/I fimbriae were also recognized by fimbriae with high sequence similarity to CFA/I, i.e., CS1 (major subunit, 55% homology to CFA/I) and CS4 (major subunit, 60% homology). In contrast, CS7 (major subunit, 20% homology) displayed weak binding to isoglobotriaosylceramide and lactosylceramide with phytosphingosine and hydroxy fatty acids but not to the other glycosphingolipids recognized by CFA/I. The detection limit of CS7 for isoglobotriaosylceramide and lactosylceramide was approximately 1 µg, while the detection limits of both CFA/I and CS4 for all binding-active compounds, except glucosylceramide, was below 0.4 µg, in line with the results presented above.
|
View this table: [in a new window] |
TABLE 2. Comparison of glycosphingolipid binding by 125I-labeled CFs
|
![]() View larger version (45K): [in a new window] |
FIG. 8. Binding of CFA/I fimbriae of ETEC to nonacid glycosphingolipids of human small intestine. The glycosphingolipids were separated on aluminum-backed silica gel plates and visualized with anisaldehyde (A). Duplicate chromatograms were incubated with 125I-labeled CFA/I fimbriae (B) and monoclonal antibodies directed against the Lea determinant (C), followed by autoradiography for 12 h, as described in Materials and Methods. The solvent system used was chloroform-methanol-water (60:35:8, by volume). Lanes: 1 to 3, nonacid glycosphingolipids of human small intestine of three different individuals (40 µg/lane); 4, reference neolactotetraosylceramide (Galß4GlcNAcß3Galß4Glcß1Cer) (4 µg); 5, reference galactosylceramide (Galß1Cer) (4 µg); 6, reference Lea pentaglycosylceramide [Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (4 µg).
|
![]() View larger version (75K): [in a new window] |
FIG. 9. Effect of preincubation of CFA/I fimbriae with oligosaccharides. Radiolabeled CFA/I fimbriae were incubated with Lea pentasaccharide (1 mg/ml) in PBS for 2 h at room temperature. The suspensions were then utilized in a chromatogram binding assay. Panels: A, binding of CFA/I fimbriae alone; B, binding of CFA/I fimbriae incubated with Lea pentasaccharide. The lanes contained dilutions of glucosylceramide (Glcß1Cer), lactosylceramide with hydroxy ceramide (Galß4Glcß1Cer), isoglobotriaosylceramide (Gal 3Galß4Glcß1Cer), and Lea pentaglycosylceramide [Galß3(Fuc 4)GlcNAcß3Galß4Glcß1Cer] (0.1 to 0.4 µg of each compound). The glycosphingolipids were separated on aluminum-backed silica gel plates with chloroform-methanol-water (60:35:8, by volume) as the solvent system, and the binding assay was performed as described in Materials and Methods. Autoradiography was performed for 12 h.
|
|
|
|---|
Requirement of a certain ceramide species for binding to occur, like the requirement of hydroxy fatty acids and/or phytosphingosine for CFA/I binding to lactosylceramide, has been reported for antibodies, bacterial toxins, and K99-fimbriated E. coli, as well as other lactosylceramide-binding bacteria, including H. pylori (reference 2 and references therein). In the case of lactosylceramide recognition, it has been proposed that the selectivity is due to binding of a conformation of lactosylceramide in which the oxygen of the fatty acid hydroxyl group forms a hydrogen bond with the hydroxymethyl group of the glucose (2). Unlike other lactosylceramide-recognizing bacteria, CFA/I-fimbriated E. coli binds to glucosylceramide. However, the glucosylceramide binding is relatively weak, indicating that although the binding epitope includes parts of the internal glucose, addition of terminal ß4-linked galactose, yielding lactosylceramide, results in a more optimal binding epitope.
In order to investigate which fimbrial proteins were associated with the carbohydrate-binding properties observed in these experiments, a mutant was generated in which the cfaE gene encoding the minor tip protein was deleted. Despite a dramatic reduction in CFA/I expression in this strain, fimbriae could be detected by inhibition enzyme-linked immunosorbent assay, observed by electron microscopy, and purified sufficiently for use in binding assays. In agreement with previous findings in which a point mutation in the tip protein was able to compromise the hemagglutination capacity of CFA/I fimbriae (1), the recombinant bacteria expressing the tipless fimbriae were no longer able to agglutinate human erythrocytes. However, the bacteria expressing these tipless fimbriae still bound to the glycosphingolipids recognized by native fimbriae, demonstrating that the glycosphingolipid-binding site(s) resides within the major CfaB subunit. It thus seems that CFA/I fimbriae have multiple binding sites. Glycosphingolipid binding is mediated by the major CfaB subunit, whereas interaction with unidentified receptors on human erythrocytes and Caco-2 cells is mediated by CfaE, the minor tip protein (1). Indeed, previous findings do support a binding capacity residing with CfaB, since monoclonal antibodies directed against this protein could inhibit the binding of CFA/I-expressing cells to human jejunal cells and prevent fluid accumulation induced by CFA/I-positive bacteria in rabbit intestinal loops (29).
An interesting parallel to our observations is found in the S fimbriae of meningitis-associated E. coli. The minor tip protein SfaS interacts with NeuAc
3Gal-carrying glycoproteins (23, 24), whereas the major subunit SfaA binds to sulfatide, seminolipid, galactosylceramide, and lactosylceramide (27). Hemagglutination induced by S-fimbriated E. coli is abolished when the sfaS gene is deleted (12), but these bacteria still adhere to human endothelial cells (25). Also, the well-characterized Gal
4Gal-binding P fimbriae of uropathogenic E. coli seems to have multiple binding capacities, since it interacts with fibronectin in a manner that is independent of Gal
4Gal-binding tip protein PapG (36).
The broader carbohydrate recognition pattern of CFA/I fimbriae compared to lactosylceramide-binding bacteria suggests either that the binding site is more permissive or that there is more than one binding site within the protein. However, the binding of lactosylceramide, isoglobotriaosylceramide, neolactotetraosylceramide, and the Lea pentaglycosylceramide could all be inhibited by incubating the CFA/I fimbriae with lactose or Lea pentasaccharide, suggesting that these compounds are accommodated in the same carbohydrate binding. Final resolution of this issue must, however, await cocrystallization of CfaB with binding-active saccharides.
The relevance of the glycosphingolipid-binding capacities shown in this study to the CFA/I-mediated adhesion of ETEC to host cells during colonization has yet to be determined. However, experiments with glycosphingolipid fractions isolated from human small intestine demonstrated that CFA/I bound in the mono-, di-, and triglycosylceramide regions in the nonacid fractions from the three individuals tested. In two of these individuals, binding to a compound comigrating with the Lea pentaglycosylceramide was observed. In the epithelial cells of human small intestine monohexosylceramides (galactosylceramide and glucosylceramide), blood group ABH (type 1 chain) and Lewis glycolipids with five to seven sugar residues are the major glycolipid constituents and the expression of major blood groups glycosphingolipids is in agreement with the ABO, Lewis, and secretor phenotype of the individuals (5). There are also trace amounts of Lex- and Ley-terminated glycosphingolipids. In addition, Lex, Ley, and H type 2 determinants are found on glycoproteins of human small intestinal epithelial cells (10). Several of the CFA/I-binding compounds such as glucosylceramide-, Lea-, Lex-, Ley-, and H type 2-terminated glycoconjugates may thus feasibly act as targets for CFA/I-mediated adherence. Isoglobotriaosylceramide, on the other hand, has been found in, e.g., dog intestine (14) but not in humans, while gangliotriaosylceramide and gangliotetraosylceramide have not been chemically identified in peripheral human tissues.
In conclusion, we have demonstrated that the major CfaB subunit of CFA/I fimbriae is a carbohydrate-binding protein which specifically interacts with a number of carbohydrate sequences that are present in human small intestinal glycosphingolipids and glycoproteins in substantial quantities. Our findings suggest that the carbohydrate-binding activity contributes to the attachment of CFA/I-fimbriated E. coli to host intestinal epithelium and may be a basis for the rational design of receptor saccharide analogues for inhibition of the adhesion of CFA/I-expressing ETEC and also ETEC carrying CFA/I-related fimbriae.
|
|
|---|
2-3 galactosides. Biochem. Biophys. Res. Commun. 111:456-461.[CrossRef][Medline]This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»